These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1071668)

  • 21. Differentiation of exercise-induced metabolic responses during selective beta 1- and beta 2-antagonism.
    Hespel P; Lijnen P; Vanhees L; Fagard R; Fiocchi R; Moerman E; Amery A
    Med Sci Sports Exerc; 1986 Apr; 18(2):186-91. PubMed ID: 3010028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Splanchnic and leg exchange of glucose, amino acids, and free fatty acids during exercise in diabetes mellitus.
    Wahren J; Hagenfeldt L; Felig P
    J Clin Invest; 1975 Jun; 55(6):1303-14. PubMed ID: 1133176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of bunitrolol on heart rate, metabolic parameters during physical exercise, and performance].
    Keul J; Lehmann M; Wybitul K
    Arzneimittelforschung; 1981; 31(11):1948-53. PubMed ID: 6119096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central haemodynamic effects in man of intravenous d-alprenolol during rest and exercise.
    Ekelund LG; Melcher A; Orö L
    Eur J Clin Pharmacol; 1971 Sep; 3(4):198-203. PubMed ID: 5151303
    [No Abstract]   [Full Text] [Related]  

  • 25. The actions of the beta-adrenoceptor blocking agents propranolol and metoprolol in the maximally exercised horse.
    Snow DH; Summers RJ; Guy PS
    Res Vet Sci; 1979 Jul; 27(1):22-9. PubMed ID: 574307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemodynamic long-term effects of a new beta-adrenoceptor blocking drug, atenolol (ICI 66082), in essential hypertension.
    Lund-Johansen P
    Br J Clin Pharmacol; 1976 Jun; 3(3):445-51. PubMed ID: 973971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of nisoldipine on systemic and leg blood flow, oxygen transport and metabolism, and hemodynamics during exercise in effort angina pectoris.
    Ram J; Freedman SB; Ogasawara S; Thomson A; Kelly DT
    Am J Cardiol; 1989 Apr; 63(12):802-6. PubMed ID: 2929436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.
    Seideman P; Borg KO; Haglund K; Von Bahr C
    Br J Clin Pharmacol; 1987 Mar; 23(3):267-71. PubMed ID: 3567041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic and forearm haemodynamic and metabolic effects of racemic propranolol or D-propranolol in healthy subjects.
    Hartling OJ; Svendsen TL; Trap-Jensen J
    Clin Sci (Lond); 1981 Jun; 60(6):675-9. PubMed ID: 7249547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of sympathetic cardiovascular reflexes and urinary catecholamines when selecting patients for antihypertensive treatment with beta-adrenergic blocking drugs.
    Iisalo E; Lehtonen A
    Ann Clin Res; 1975 Apr; 7(2):71-5. PubMed ID: 1103708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity.
    Collste P; Haglund K; Frisk-Holmberg M; Orme ML; Rawlins MD; Ostman J
    Eur J Clin Pharmacol; 1976 Jun; 10(2):89-95. PubMed ID: 964292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diet induced changes in sympatho-adrenal activity during submaximal exercise in relation to substrate utilization in man.
    Jansson E; Hjemdahl P; Kaijser L
    Acta Physiol Scand; 1982 Feb; 114(2):171-8. PubMed ID: 6814194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of alprenolol and methyldopa in previously untreated essential hypertension.
    Vedin JA; Wilhelmsson CE; Werkö L
    Br Heart J; 1973 Dec; 35(12):1285-92. PubMed ID: 4586374
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of beta adrenergic blocking agents (alprenolol and propranolol) in essential hypertension.
    Nik-Akhtar B; Rashed MA; Khakpour M
    Angiology; 1975 Apr; 26(4):339-43. PubMed ID: 1119734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of metoprolol and alprenolol on the metabolic, hormonal, and haemodynamic response to insulin-induced hypoglycaemia in hypertensive, insulin-dependent diabetics.
    Ostman J; Arner P; Haglund K; Juhlin-Dannfelt A; Nowak J; Wennlund A
    Acta Med Scand; 1982; 211(5):381-5. PubMed ID: 7051762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-adrenoceptor-blocking agents in the management of hypertension.
    Prichard BN
    Cardiology; 1979; 64 Suppl 1():44-87. PubMed ID: 42488
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of a rapid change in muscle glycogen availability on metabolic and hormonal responses during exercise.
    Lavoie JM; Hélie R; Cousineau D
    Eur J Appl Physiol Occup Physiol; 1984; 53(1):57-62. PubMed ID: 6391918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspects of hormonal regulation of lipolysis during exercise: effects of chronic beta-receptor blockade.
    Franz IW; Lohmann FW; Koch G; Quabbe HJ
    Int J Sports Med; 1983 Feb; 4(1):14-20. PubMed ID: 6132891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy.
    Pedersen EB; Kornerup HJ
    Eur J Clin Pharmacol; 1977 Oct; 12(2):93-6. PubMed ID: 923630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.
    Hartikainen M; Heikkilä J
    Ann Clin Res; 1976 Apr; 8(2):85-92. PubMed ID: 779590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.